Impact of Nitrate Ingestion on Protein Synthesis

NCT ID: NCT01473576

Last Updated: 2016-04-15

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-31

Study Completion Date

2013-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A diet rich in leafy green vegetables has been shown to reduce the risk of developing chronic metabolic disease. The health benefits from these particular vegetables may be attributed to their high nitrate content. Recent work suggests that dietary nitrate triggers endogenous nitric oxide release, thereby stimulating vasodilation and improving muscle perfusion in an insulin-independent manner. We hypothesize that in an insulin-resistant state, nitrate co-ingestion will increase muscle perfusion, thereby improving post-prandial delivery of nutrients to skeletal muscle tissue. Specifically, a more efficient delivery of food derived amino acids will stimulate post-prandial muscle protein synthesis and, as such, compensate for a blunted muscle protein synthetic response to food intake in the elderly. This proposal will investigate the efficacy of nitrate co-ingestion as a means to augment muscle protein synthesis in elderly, type 2 diabetes patients and may lead to a novel therapy in the clinical care of type 2 diabetes patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Muscle Protein Synthesis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Nitrate

Sodium nitrate ingestion prior to ingesting intrinsically labeled protein

Group Type EXPERIMENTAL

Nitrate

Intervention Type DIETARY_SUPPLEMENT

0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)

Sodium chloride

Sodium chloride placebo group

Group Type PLACEBO_COMPARATOR

Sodium chloride

Intervention Type DIETARY_SUPPLEMENT

0.15 mmol sodium chloride dissolved in 250 mL water.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Nitrate

0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)

Intervention Type DIETARY_SUPPLEMENT

Sodium chloride

0.15 mmol sodium chloride dissolved in 250 mL water.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Male
* Aged between 70-85 years
* BMI \< 30 kg/m2
* Non insulin-dependent diabetes mellitus type 2 patients (T2DM) ( \>1 y since diagnoses)

Exclusion Criteria

* Smoking
* Hypertension (according to WHO criteria)\[29\] and/or cardiovascular disease treated with medication containing nitrates and/or having vasodilatory effects
* Use of medication, except for oral blood glucose lowering medication
* Use of insulin
* All co-morbidities interacting with mobility and muscle metabolism of the lower limbs (e.g. arthritis, spasticity/rigidity, all neurological disorders and paralysis).
* HbA1c \> 10.0% (86 mmol/mol)
* Donated blood in last 3 months
* Diagnosed impaired renal or liver function
* Myocardial infarction within the last 3 years
* Gastric acid inhibitors
* Use of anti-coagulants
Minimum Eligible Age

70 Years

Maximum Eligible Age

85 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Maastricht University Medical Center

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Luc van Loon, PhD

Role: STUDY_DIRECTOR

Maastricht University

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Maastricht University

Maastricht, Limburg, Netherlands

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Netherlands

References

Explore related publications, articles, or registry entries linked to this study.

Gorissen SHM, Trommelen J, Kouw IWK, Holwerda AM, Pennings B, Groen BBL, Wall BT, Churchward-Venne TA, Horstman AMH, Koopman R, Burd NA, Fuchs CJ, Dirks ML, Res PT, Senden JMG, Steijns JMJM, de Groot LCPGM, Verdijk LB, van Loon LJC. Protein Type, Protein Dose, and Age Modulate Dietary Protein Digestion and Phenylalanine Absorption Kinetics and Plasma Phenylalanine Availability in Humans. J Nutr. 2020 Aug 1;150(8):2041-2050. doi: 10.1093/jn/nxaa024.

Reference Type DERIVED
PMID: 32069356 (View on PubMed)

Kouw IW, Gorissen SH, Burd NA, Cermak NM, Gijsen AP, van Kranenburg J, van Loon LJ. Postprandial Protein Handling Is Not Impaired in Type 2 Diabetes Patients When Compared With Normoglycemic Controls. J Clin Endocrinol Metab. 2015 Aug;100(8):3103-11. doi: 10.1210/jc.2015-1234. Epub 2015 Jun 2.

Reference Type DERIVED
PMID: 26037513 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

11-3-057

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

NWT03 and Arterial Stiffness
NCT02561663 COMPLETED NA
Effect of NWT-03 on Blood Pressure
NCT02144740 COMPLETED NA